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SUMMARY · Abdominal pain is a complication of endoscopic retrograde cholangiopancreatography
(ERCP) and endoscopic sphincterotomy (EST). The aim of this trial was to investigate the effects of
octreotide acetate in the prevention of abdominal pain in patients undergoing therapeutic ERCP. A
double-blind study was carried out in 209 subjects who were randomly allocated to two groups (A
and B). Group A (104 patients) received 0.5 mg of octreotide acetate subcutaneously one hour prior
to ERCP; and group B (105 patients) were given placebo. Patients were assessed 2 and 24 hours
following endoscopy for the following parameters: presence and character of abdominal pain, re-
quirements of analgetics. Thirty-nine (18%) patients complained of post-ERCP pain, i.e. ten in group
A and 29 in group B, all of them treated with analgetics. Of the ten group A patients, symptoms of
acute pancreatitis were identified in four (3.85%) patients versus ten (9.52%) patients in the control
group B. The results obtained in the study seem to indicate that octreotide pretreatment significantly
reduced the development of post-ERCP pain.
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Introduction
Complications related to endoscopic retrograde cho-
langiopancreatography (ERCP) represent a serious medi-
cal problem for both the patient and physician. Possible
complications following this procedure include a rise in
serum amylase and lipase, acute pancreatitis, and epigas-
tric pain1. The incidence of pancreatitis as the most se-
vere complication following ERCP has been variously
assessed to lie between 2% and 20%1. However, the fre-
quency of biochemical abnormalities (increased serum
pancreatic enzyme values) without clinical manifestations
of acute pancreatitis is much higher, i.e. as much as 75%
of patients according to a review by Booth et al.2, while
episodes of post-ERCP epigastric pain have not been fully
investigated.
The pathogenesis of post-ERCP pain is not known.
Some cases might have previously been explained by
forced filling of the pancreatic duct and use of ionic con-
trast medium3. However, avoiding ‘acinarization’ in pan-
creatogram and changing to nonionic contrast medium
have not made post-ERCP pancreatitis disappear. Like-
wise, the presence of abdominal pain, with or without se-
rum pancreatic enzyme increment, remains another sce-
nario that may be expected following ERCP4.
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Few drugs have been used in the prevention of post-
ERCP complications, among which octreotide, a soma-
tostatin analogue (Sandostatin, Sandoz) has been assessed
due to its unique pharmacologic properties5-7. Several
studies in healthy volunteers have shown inhibition of
baseline and stimulated exocrine pancreatic secretion7-9.
Likewise, animal studies have shown an impairment in the
pancreatic enzyme response after an infusion of octreo-
tide10. In one study, pancreatitis was induced by ligature
of the pancreatic duct11, a model that is probably more
analogous to post-ERCP pancreatitis. Octreotide impro-
ved the enzyme response, histology, and survival.
Several studies have dealt with evaluating the prophy-
lactic effects of octreotide on ERCP-induced pancreatic
reactions, but the results of such studies have been con-
flicting and few authors have dealt specifically with the
problem of post-ERCP epigastric pain12-16. Our group
had previously investigated the single-dose prophylactic
effects of octreotide in preventing the increase in serum
pancreatic enzymes in a group of hospitalized patients
undergoing therapeutic ERCP17. The focus of this paper
will be to detail the effects of prophylactic octreotide ad-
ministration on abdominal pain, observed in the previ-
ously mentioned population, i.e. in the patients who re-
ceived a single dose of octreotide acetate prior to ERCP.
Patients and Methods
During a four-year period (September 1994 · Sep-
tember 1998), a total of 209 subjects with indications for
therapeutic ERCP were enrolled in the trial designed as
a randomized, double-blind study. Randomization was
performed using the Microsoft Excel software. Subjects
were allocated to either of two groups (A and B), and un-
derwent prophylactic treatment with either octreotide ac-
etate or placebo (Table 1). Blinding was ensured by the
study solutions being prepared by the same individual not
present during the procedure but given the list of random-
ization. Patients allocated to group A were administered
0.5 mg of octreotide subcutaneously one hour prior to the
endoscopic procedure. Patients from group B (placebo
group) were administered isotonic sodium chloride in the
protocolar fashion. Prior to the procedure (which was al-
ways performed by the same endoscopist), all patients
underwent the same premedication which consisted of
sublingual administration of nitroglycerin, intravenous
administration of 10 mg diazepam, and pharyngeal an-
esthesia with Xylocaine spray. Likewise, all patients re-
ceived antibiotic prophylaxis in the form of ciprofloxacin
90 minutes before ERCP. All patients were hospitalized
and confined to bed for at least 24 hours following ERCP.
Fasting was maintained for a minimum of six hours.
Assessment of abdominal pain was performed prior to
ERCP, and 2 and 24 hours after ERCP. Pain was graded
using a simple scoring system in which patients catego-
rized their pain into one of 4 categories assigned values
from 0 to 4, as follows: 0 · no pain, 1 · mild pain, 2 · mo-
derate pain, and 3 · severe pain. Patients who complained
of pain were asked about its location and character,
whether it was similar to the pre-existing pain, and whet-
her there was radiation to the back. For those patients who
required pain medication, the type of medication, route
of administration and dose were recorded.
ERCP was performed using an Olympus JF1T20
endoscope. Contrast medium (Urografin, Schering AG
Pharma, Germany) was injected manually in a controlled,
titrated fashion under fluoroscopic control. When indi-
cated, sphincterotomy was performed using a standard
Erlangen type sphincterotomy. Selective cannulation was
performed in all patients. Ductal cannulation was rated
as ‘easy’ if cannulation could be readily achieved, or ‘dif-
ficult’ if it required repeated attempts.
ERCP pancreatitis was defined as the presence of
abdominal pain, tenderness, nausea and vomiting begin-
ning after ERCP and lasting for at least 24 hours, associ-
ated with an increase in serum amylase and/or lipase lev-
els greater than three-fold upper ‘normal’ limit. It was
graded as mild if admission or prolongation of the planned
admission by 1 to 3 days was required; moderate for hos-
pitalization not longer than 10 days; and severe for any
intensive care unit admission, hospital stay of more than
10 days, hemorrhagic pancreatitis, phlegmon, or pseu-
docyst formation.
Comparison of data between the two groups was done
by use of Cochran-Mantel-Haenszel analysis. A p value
of  0.05 or less was considered as indicating statistical sig-
nificance.
The study was approved by the Hosptial Ethics Com-
mittee. Prior to enrollment in the study, all patients were
informed about the nature of the study, and a written in-
formed consent was obtained.
Results
Of 209 patients enrolled in the study, 104 were treated
with octreotide, while 105 patients were given placebo and
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served as a control group (Table 1). The mean duration
of endoscopic procedure in the octreotide and control
group was 34 and 31 minutes, respectively, with an aver-
age of 15 ml of contrast medium used in all patients. No
significant side effects attributable to octreotide were ob-
served during the study.
Table 1. Patient characteristics
Group A Group B
Patients (octreotide (control group;
acetate) placebo)
n 104 105
Mean age (yrs) 56 54
Sex (M/F) 40/64 45/60
Thirty-nine patients complained of pain following
therapeutic endoscopic procedure, i.e. ten group A pa-
tients and 29 group B patients, all of them treated with
analgesics (Table 2). Out of the ten group A patients,
symptoms of acute pancreatitis were identified in four
(3.85%) patients versus ten (9.52%) in the control group.
The patients who developed acute pancreatitis were in-
cluded in the highest score group.
Table 2. Abdominal pain score according to patient group
Group A Group B
(octreotide (control group;
Pain score acetate) placebo)
(n = 104) (n = 105)
n (%) n (%)
0 94 (90.3) 76 (73)
1 5 (4.8) 2 (1.9)
2 1 (1.0) 10 (9.5)
3 4 (3.8) 17 (16.2)
Level of significance p<0.01*
* statistically significant different between-group pain score dis-
tribution
Apart from the patients who developed acute pancre-
atitis and were treated conventionally, the patients with
mild and moderate pain (score 1 or 2) were treated with
i.v. metamisol (Analgin, Pliva, Zagreb, Croatia), while
those with a pain score 3 and without symptoms of acute
pancreatitis were treated with s.c. pentazocine (Fortral,
Krka, Novo Mesto, Slovenia).
Discussion
Complications related to ERCP pose a serious medi-
cal problem for both the patient and the physician. One
of the procedure complications is the development of
post-ERCP epigastric pain. Since somatostatin has been
demonstrated to relieve post-ERCP epigastric pain18, it
seemed reasonable to presume that octreotide, a potent so-
matostatin analogue, might elicit a similar effect. In the
present study, we tried to determine whether octreotide
acetate prophylaxis could decrease the incidence of epi-
gastric pain in patients undergoing therapeutic ERCP. We
hoped to help clarify the issue by comparing the reported
presence and severity of pain in the group of patients ad-
ministered a single dose of octreotide s.c. one hour before
the endoscopic procedure (group A) and in the group of
patients who received isotonic sodium chloride by the
same route of administration. Our choice of a single dose
instead of longterm octreotide administration, described
by Testoni et al.16, was based on the fact that in spite of
the octreotide half-life of 90-120 minutes with s.c. admin-
istration, its pharmacodynamic action lasts for up to 8-12
hours8, i.e. for a period of time when the post-ERCP
complications develop.
Post-ERCP epigastric pain with or without the devel-
opment of pancreatitis is commonly observed, however,
the cause of its occurrence has not yet been fully clarified.
One explanation could be the reduced pancreatic secre-
tion against the temporarily obstructred sphincter of
Oddicaused by both instrumental manipulation and for-
ced filling of the pancreatic duct 5,19,20. It has recently
been demonstrated that octreotide acetate, among its
other pharmacologic actions, restrains the Oddi’s sphinc-
ter motility 21. This type of drug action should reduce
pressure in the intrapancreatic ducts, thus helping prevent
the occurrence of acute pancreatitis.
Our study in 209 patients randomized to octreotide
or placebo administration showed a significant effect of
octreotide in preventing the development of post-ERCP
abdominal pain (Table 2). Thirty-nine patients com-
plained of post-ERCP pain, i.e. ten patients on octreotide
and 29 patients from the control group receiving placebo
(p<0.05), all of them treated with analgesics. Out of the
ten octreotide group patients, symptoms of acute pancre-
atitis were recorded in four patients, as compared with ten
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out of 29 control group patients. In the patients adminis-
tered octreotide who developed abdominal pain, there was
a tendency to mild (five octreotide group patients versus
two control group patients) rather than moderate pain
(one octreotide group patient versus ten control group pa-
tients), with lower use of analgesics. In the octreotide
group, severe pain was only recorded in patients who were
classified as having developed acute pancreatitis, while in
the placebo group severe pain was reported by seven pati-
ents otherwise free from other indicators of acute pancreatitis
(tenderness, nausea and vomiting beginning after ERCP
and lasting for at least 24 hours, associated with an increase
in serum amylase and/or lipase levels greater than three-fold
upper normal limits).
In conclusion, the results obtained in the present study
seem to indicate that a single application of octreotide can
prevent the development of abdominal pain after ERCP,
with a tendency to mild pain when it does occur, and with
a lower use of analgesics. Therefore, it appears that octreo-
tide prophylaxis might have an important role in thera-
peutic ERCP procedures.
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Saæetak
RANDOMIZIRANO DVOSTRUKO-SLIJEPO ISPITIVANJE U»INKOVITOSTI OKTREOTID ACETATA
U SPRJE»AVANJU ABDOMINALNE BOLI NAKON TERAPIJSKE ENDOSKOPSKE RETROGRADNE
KOLANGIOPANKREATOGRAFIJE
M. Duvnjak, V. Supanc, V. ©imiËeviÊ, D. Hrabar, B. Troskot, L. SmirËiÊ-Duvnjak, R. OstojiÊ2 i S. Rado¹eviÊ3
Abdominalna bol je Ëesta komplikacija endoskopske retrogradne kolangiopankreatografije (ERCP) i endoskopske
sfinkterotomije (EST). Cilj ovoga ispitivanja bio je istraæiti uËinke oktreotid acetata u prevenciji abdominalne boli u bolesnika
podvrgnutih ERCP-u. U ovu dvostruko-slijepu studiju bilo je ukljuËeno 209 bolesnika koji su nasumce podijeljeni u dvije
skupine (A i B). Bolesnici skupine A (n=104) primili su 0,5 mg oktreotid acetata supkutano jedan sat prije ERCP-a, dok su
bolesnici skupine B (n=105) dobili placebo. Procjena kliniËkih parametara (prisutnost i teæina abdominalne boli te potreba za
analgeticima) provedena je u bolesnika 2 i 24 sata nakon endoskopije. Ukupno se 39 (18%) bolesnika æalilo na bol nakon
ERCP-a, tj. desetoro u skupini A i 29 u skupini B, a svi su oni lijeËeni analgeticima. Od desetoro  bolesnika iz skupine A
simptomi akutnog pankreatitisa zabiljeæeni su u Ëetvoro (3,85%) bolesnika, u usporedbi s desetoro (9,52%) bolesnika u
kontrolnoj skupini B. Rezultati ovoga ispitivanja pokazali su da je prethodno davanje oktreotida znaËajno smanjilo nastup
abdominalne boli nakon ERCP-a.
KljuËne rijeËi:  Kolangiopankreatografija, endoskopska, retrogradna, nuspojave; Oktreotid, terapijska primjena; Pankreatitis, preven-
cija i suzbijanje.
